ProKidney Corp.PROKNASDAQ
Loading
R&D Expense Growth Recovery in ProgressRecovering
Percentile Rank42
3Y CAGR-64.8%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
-64.8%/yr
Quarterly compound
Percentile
P42
Within normal range
vs 3Y Ago
0x
Contraction
Streak
2 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q3 2025 | 3.63% |
| Q2 2025 | -5.07% |
| Q1 2025 | -31.47% |
| Q4 2024 | 27.30% |
| Q3 2024 | 6.28% |
| Q2 2024 | 7.97% |
| Q1 2024 | 20.89% |
| Q4 2023 | -30.03% |
| Q3 2023 | 22.13% |
| Q2 2023 | 2.92% |
| Q1 2023 | 22.63% |
| Q4 2022 | -1.15% |
| Q3 2022 | 82.83% |
| Q2 2022 | -59.43% |
| Q1 2022 | 166.64% |
| Q4 2021 | -27.52% |
| Q3 2021 | 34.40% |
| Q2 2021 | 11.26% |
| Q1 2021 | 54.36% |
| Q4 2020 | 0.00% |